United States Pulmonary Drugs Market Report 2018
![](/report_cover/6975/united-states-pulmonary-drugs-market-report-2018_qyresearch_en.gif)
In this report, the United States Pulmonary Drugs market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.
Geographically, this report splits the United States market into seven regions:
Geographically, this report splits the United States market into seven regions:
- The West
- Southwest
- The Middle Atlantic
- New England
- The South
- The Midwest
- with sales (volume), revenue (value), market share and growth rate of Pulmonary Drugs in these regions, from 2013 to 2025 (forecast).
- AstraZeneca plc
- Bayer AG
- Teva Pharmaceutical Industries Ltd
- Actelion Pharmaceuticals, Inc.
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Novartis AG
- GlaxoSmithKline plc
- Sunovion Pharmaceuticals
- Inhaled Corticosteroids (ICS)
- Long-Acting Beta2-Agonists (LABA)
- Antihistamine
- Vasodilators
- Short-Acting Beta2-Agonists (SABA)
- Anticholinergics
- Combination Drugs
- MAbs
- Enzymes
- Antibiotics & Antileukotrienes
- Asthma & COPD
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
United States Pulmonary Drugs Market Report 2018
1 PULMONARY DRUGS OVERVIEW
1.1 Product Overview and Scope of Pulmonary Drugs
1.2 Classification of Pulmonary Drugs by Product Category
1.2.1 United States Pulmonary Drugs Market Size (Sales Volume) Comparison by Type (2013-2025)
1.2.2 United States Pulmonary Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
1.2.3 Inhaled Corticosteroids (ICS)
1.2.4 Long-Acting Beta2-Agonists (LABA)
1.2.5 Antihistamine
1.2.6 Vasodilators
1.2.7 Short-Acting Beta2-Agonists (SABA)
1.2.8 Anticholinergics
1.2.9 Combination Drugs
1.2.10 MAbs
1.2.11 Enzymes
1.2.12 Antibiotics & Antileukotrienes
1.3 United States Pulmonary Drugs Market by Application/End Users
1.3.1 United States Pulmonary Drugs Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
1.3.2 Asthma & COPD
1.3.3 Allergic Rhinitis
1.3.4 Pulmonary Arterial Hypertension
1.3.5 Cystic Fibrosis
1.4 United States Pulmonary Drugs Market by Region
1.4.1 United States Pulmonary Drugs Market Size (Value) Comparison by Region (2013-2025)
1.4.2 The West Pulmonary Drugs Status and Prospect (2013-2025)
1.4.3 Southwest Pulmonary Drugs Status and Prospect (2013-2025)
1.4.4 The Middle Atlantic Pulmonary Drugs Status and Prospect (2013-2025)
1.4.5 New England Pulmonary Drugs Status and Prospect (2013-2025)
1.4.6 The South Pulmonary Drugs Status and Prospect (2013-2025)
1.4.7 The Midwest Pulmonary Drugs Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Pulmonary Drugs (2013-2025)
1.5.1 United States Pulmonary Drugs Sales and Growth Rate (2013-2025)
1.5.2 United States Pulmonary Drugs Revenue and Growth Rate (2013-2025)
2 UNITED STATES PULMONARY DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS
2.1 United States Pulmonary Drugs Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Pulmonary Drugs Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Pulmonary Drugs Average Price by Players/Suppliers (2013-2018)
2.4 United States Pulmonary Drugs Market Competitive Situation and Trends
2.4.1 United States Pulmonary Drugs Market Concentration Rate
2.4.2 United States Pulmonary Drugs Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Pulmonary Drugs Manufacturing Base Distribution, Sales Area, Product Type
3 UNITED STATES PULMONARY DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)
3.1 United States Pulmonary Drugs Sales and Market Share by Region (2013-2018)
3.2 United States Pulmonary Drugs Revenue and Market Share by Region (2013-2018)
3.3 United States Pulmonary Drugs Price by Region (2013-2018)
4 UNITED STATES PULMONARY DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)
4.1 United States Pulmonary Drugs Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Pulmonary Drugs Revenue and Market Share by Type (2013-2018)
4.3 United States Pulmonary Drugs Price by Type (2013-2018)
4.4 United States Pulmonary Drugs Sales Growth Rate by Type (2013-2018)
5 UNITED STATES PULMONARY DRUGS SALES (VOLUME) BY APPLICATION (2013-2018)
5.1 United States Pulmonary Drugs Sales and Market Share by Application (2013-2018)
5.2 United States Pulmonary Drugs Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities
6 UNITED STATES PULMONARY DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA
6.1 AstraZeneca plc
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Pulmonary Drugs Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 AstraZeneca plc Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.1.4 Main Business/Business Overview
6.2 Bayer AG
6.2.2 Pulmonary Drugs Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Bayer AG Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.2.4 Main Business/Business Overview
6.3 Teva Pharmaceutical Industries Ltd
6.3.2 Pulmonary Drugs Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Teva Pharmaceutical Industries Ltd Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.3.4 Main Business/Business Overview
6.4 Actelion Pharmaceuticals, Inc.
6.4.2 Pulmonary Drugs Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.4.4 Main Business/Business Overview
6.5 Boehringer Ingelheim GmbH
6.5.2 Pulmonary Drugs Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Boehringer Ingelheim GmbH Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.5.4 Main Business/Business Overview
6.6 F. Hoffmann-La Roche Ltd.
6.6.2 Pulmonary Drugs Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.6.4 Main Business/Business Overview
6.7 Merck & Co., Inc.
6.7.2 Pulmonary Drugs Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Merck & Co., Inc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.7.4 Main Business/Business Overview
6.8 Novartis AG
6.8.2 Pulmonary Drugs Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Novartis AG Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.8.4 Main Business/Business Overview
6.9 GlaxoSmithKline plc
6.9.2 Pulmonary Drugs Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 GlaxoSmithKline plc Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.9.4 Main Business/Business Overview
6.10 Sunovion Pharmaceuticals
6.10.2 Pulmonary Drugs Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Sunovion Pharmaceuticals Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.10.4 Main Business/Business Overview
7 PULMONARY DRUGS MANUFACTURING COST ANALYSIS
7.1 Pulmonary Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Pulmonary Drugs
8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS
8.1 Pulmonary Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Pulmonary Drugs Major Manufacturers in 2017
8.4 Downstream Buyers
9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 MARKET EFFECT FACTORS ANALYSIS
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 UNITED STATES PULMONARY DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)
11.1 United States Pulmonary Drugs Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Pulmonary Drugs Sales Volume Forecast by Type (2018-2025)
11.3 United States Pulmonary Drugs Sales Volume Forecast by Application (2018-2025)
11.4 United States Pulmonary Drugs Sales Volume Forecast by Region (2018-2025)
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
The report requires updating with new data and is sent in 2-3 business days after order is placed.
1 PULMONARY DRUGS OVERVIEW
1.1 Product Overview and Scope of Pulmonary Drugs
1.2 Classification of Pulmonary Drugs by Product Category
1.2.1 United States Pulmonary Drugs Market Size (Sales Volume) Comparison by Type (2013-2025)
1.2.2 United States Pulmonary Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
1.2.3 Inhaled Corticosteroids (ICS)
1.2.4 Long-Acting Beta2-Agonists (LABA)
1.2.5 Antihistamine
1.2.6 Vasodilators
1.2.7 Short-Acting Beta2-Agonists (SABA)
1.2.8 Anticholinergics
1.2.9 Combination Drugs
1.2.10 MAbs
1.2.11 Enzymes
1.2.12 Antibiotics & Antileukotrienes
1.3 United States Pulmonary Drugs Market by Application/End Users
1.3.1 United States Pulmonary Drugs Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
1.3.2 Asthma & COPD
1.3.3 Allergic Rhinitis
1.3.4 Pulmonary Arterial Hypertension
1.3.5 Cystic Fibrosis
1.4 United States Pulmonary Drugs Market by Region
1.4.1 United States Pulmonary Drugs Market Size (Value) Comparison by Region (2013-2025)
1.4.2 The West Pulmonary Drugs Status and Prospect (2013-2025)
1.4.3 Southwest Pulmonary Drugs Status and Prospect (2013-2025)
1.4.4 The Middle Atlantic Pulmonary Drugs Status and Prospect (2013-2025)
1.4.5 New England Pulmonary Drugs Status and Prospect (2013-2025)
1.4.6 The South Pulmonary Drugs Status and Prospect (2013-2025)
1.4.7 The Midwest Pulmonary Drugs Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Pulmonary Drugs (2013-2025)
1.5.1 United States Pulmonary Drugs Sales and Growth Rate (2013-2025)
1.5.2 United States Pulmonary Drugs Revenue and Growth Rate (2013-2025)
2 UNITED STATES PULMONARY DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS
2.1 United States Pulmonary Drugs Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Pulmonary Drugs Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Pulmonary Drugs Average Price by Players/Suppliers (2013-2018)
2.4 United States Pulmonary Drugs Market Competitive Situation and Trends
2.4.1 United States Pulmonary Drugs Market Concentration Rate
2.4.2 United States Pulmonary Drugs Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Pulmonary Drugs Manufacturing Base Distribution, Sales Area, Product Type
3 UNITED STATES PULMONARY DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)
3.1 United States Pulmonary Drugs Sales and Market Share by Region (2013-2018)
3.2 United States Pulmonary Drugs Revenue and Market Share by Region (2013-2018)
3.3 United States Pulmonary Drugs Price by Region (2013-2018)
4 UNITED STATES PULMONARY DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)
4.1 United States Pulmonary Drugs Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Pulmonary Drugs Revenue and Market Share by Type (2013-2018)
4.3 United States Pulmonary Drugs Price by Type (2013-2018)
4.4 United States Pulmonary Drugs Sales Growth Rate by Type (2013-2018)
5 UNITED STATES PULMONARY DRUGS SALES (VOLUME) BY APPLICATION (2013-2018)
5.1 United States Pulmonary Drugs Sales and Market Share by Application (2013-2018)
5.2 United States Pulmonary Drugs Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities
6 UNITED STATES PULMONARY DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA
6.1 AstraZeneca plc
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Pulmonary Drugs Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 AstraZeneca plc Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.1.4 Main Business/Business Overview
6.2 Bayer AG
6.2.2 Pulmonary Drugs Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Bayer AG Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.2.4 Main Business/Business Overview
6.3 Teva Pharmaceutical Industries Ltd
6.3.2 Pulmonary Drugs Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Teva Pharmaceutical Industries Ltd Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.3.4 Main Business/Business Overview
6.4 Actelion Pharmaceuticals, Inc.
6.4.2 Pulmonary Drugs Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.4.4 Main Business/Business Overview
6.5 Boehringer Ingelheim GmbH
6.5.2 Pulmonary Drugs Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Boehringer Ingelheim GmbH Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.5.4 Main Business/Business Overview
6.6 F. Hoffmann-La Roche Ltd.
6.6.2 Pulmonary Drugs Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.6.4 Main Business/Business Overview
6.7 Merck & Co., Inc.
6.7.2 Pulmonary Drugs Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Merck & Co., Inc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.7.4 Main Business/Business Overview
6.8 Novartis AG
6.8.2 Pulmonary Drugs Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Novartis AG Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.8.4 Main Business/Business Overview
6.9 GlaxoSmithKline plc
6.9.2 Pulmonary Drugs Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 GlaxoSmithKline plc Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.9.4 Main Business/Business Overview
6.10 Sunovion Pharmaceuticals
6.10.2 Pulmonary Drugs Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Sunovion Pharmaceuticals Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
6.10.4 Main Business/Business Overview
7 PULMONARY DRUGS MANUFACTURING COST ANALYSIS
7.1 Pulmonary Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Pulmonary Drugs
8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS
8.1 Pulmonary Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Pulmonary Drugs Major Manufacturers in 2017
8.4 Downstream Buyers
9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 MARKET EFFECT FACTORS ANALYSIS
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 UNITED STATES PULMONARY DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)
11.1 United States Pulmonary Drugs Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Pulmonary Drugs Sales Volume Forecast by Type (2018-2025)
11.3 United States Pulmonary Drugs Sales Volume Forecast by Application (2018-2025)
11.4 United States Pulmonary Drugs Sales Volume Forecast by Region (2018-2025)
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES
Figure Product Picture of Pulmonary Drugs
Figure United States Pulmonary Drugs Market Size (K Units) by Type (2013-2025)
Figure United States Pulmonary Drugs Sales Volume Market Share by Type (Product Category) in 2017
Figure Inhaled Corticosteroids (ICS) Product Picture
Figure Long-Acting Beta2-Agonists (LABA) Product Picture
Figure Antihistamine Product Picture
Figure Vasodilators Product Picture
Figure Short-Acting Beta2-Agonists (SABA) Product Picture
Figure Anticholinergics Product Picture
Figure Combination Drugs Product Picture
Figure MAbs Product Picture
Figure Enzymes Product Picture
Figure Antibiotics & Antileukotrienes Product Picture
Figure United States Pulmonary Drugs Market Size (K Units) by Application (2013-2025)
Figure United States Sales Market Share of Pulmonary Drugs by Application in 2017
Figure Asthma & COPD Examples
Table Key Downstream Customer in Asthma & COPD
Figure Allergic Rhinitis Examples
Table Key Downstream Customer in Allergic Rhinitis
Figure Pulmonary Arterial Hypertension Examples
Table Key Downstream Customer in Pulmonary Arterial Hypertension
Figure Cystic Fibrosis Examples
Table Key Downstream Customer in Cystic Fibrosis
Figure United States Pulmonary Drugs Market Size (Million USD) by Region (2013-2025)
Figure The West Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Pulmonary Drugs Sales (K Units) and Growth Rate (2013-2025)
Figure United States Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Pulmonary Drugs Market Major Players Product Sales Volume (K Units) (2013-2018)
Table United States Pulmonary Drugs Sales (K Units) of Key Players/Suppliers (2013-2018)
Table United States Pulmonary Drugs Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Pulmonary Drugs Sales Share by Players/Suppliers
Figure 2017 United States Pulmonary Drugs Sales Share by Players/Suppliers
Figure United States Pulmonary Drugs Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Pulmonary Drugs Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Pulmonary Drugs Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Pulmonary Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Pulmonary Drugs Revenue Share by Players/Suppliers
Table United States Market Pulmonary Drugs Average Price (USD/Unit) of Key Players/Suppliers (2013-2018)
Figure United States Market Pulmonary Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2017
Figure United States Pulmonary Drugs Market Share of Top 3 Players/Suppliers
Figure United States Pulmonary Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Pulmonary Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Pulmonary Drugs Product Category
Table United States Pulmonary Drugs Sales (K Units) by Region (2013-2018)
Table United States Pulmonary Drugs Sales Share by Region (2013-2018)
Figure United States Pulmonary Drugs Sales Share by Region (2013-2018)
Figure United States Pulmonary Drugs Sales Market Share by Region in 2017
Table United States Pulmonary Drugs Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Pulmonary Drugs Revenue Share by Region (2013-2018)
Figure United States Pulmonary Drugs Revenue Market Share by Region (2013-2018)
Figure United States Pulmonary Drugs Revenue Market Share by Region in 2017
Table United States Pulmonary Drugs Price (USD/Unit) by Region (2013-2018)
Table United States Pulmonary Drugs Sales (K Units) by Type (2013-2018)
Table United States Pulmonary Drugs Sales Share by Type (2013-2018)
Figure United States Pulmonary Drugs Sales Share by Type (2013-2018)
Figure United States Pulmonary Drugs Sales Market Share by Type in 2017
Table United States Pulmonary Drugs Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Pulmonary Drugs Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Pulmonary Drugs by Type (2013-2018)
Figure Revenue Market Share of Pulmonary Drugs by Type in 2017
Table United States Pulmonary Drugs Price (USD/Unit) by Types (2013-2018)
Figure United States Pulmonary Drugs Sales Growth Rate by Type (2013-2018)
Table United States Pulmonary Drugs Sales (K Units) by Application (2013-2018)
Table United States Pulmonary Drugs Sales Market Share by Application (2013-2018)
Figure United States Pulmonary Drugs Sales Market Share by Application (2013-2018)
Figure United States Pulmonary Drugs Sales Market Share by Application in 2017
Table United States Pulmonary Drugs Sales Growth Rate by Application (2013-2018)
Figure United States Pulmonary Drugs Sales Growth Rate by Application (2013-2018)
Table AstraZeneca plc Basic Information List
Table AstraZeneca plc Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure AstraZeneca plc Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure AstraZeneca plc Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure AstraZeneca plc Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Bayer AG Basic Information List
Table Bayer AG Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Bayer AG Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Bayer AG Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Bayer AG Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Teva Pharmaceutical Industries Ltd Basic Information List
Table Teva Pharmaceutical Industries Ltd Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Teva Pharmaceutical Industries Ltd Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Teva Pharmaceutical Industries Ltd Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Teva Pharmaceutical Industries Ltd Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Actelion Pharmaceuticals, Inc. Basic Information List
Table Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Actelion Pharmaceuticals, Inc. Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Boehringer Ingelheim GmbH Basic Information List
Table Boehringer Ingelheim GmbH Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Boehringer Ingelheim GmbH Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Boehringer Ingelheim GmbH Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Boehringer Ingelheim GmbH Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table F. Hoffmann-La Roche Ltd. Basic Information List
Table F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Merck & Co., Inc. Basic Information List
Table Merck & Co., Inc. Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Merck & Co., Inc. Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Merck & Co., Inc. Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Merck & Co., Inc. Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Novartis AG Basic Information List
Table Novartis AG Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Novartis AG Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Novartis AG Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Novartis AG Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table GlaxoSmithKline plc Basic Information List
Table GlaxoSmithKline plc Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure GlaxoSmithKline plc Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure GlaxoSmithKline plc Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure GlaxoSmithKline plc Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Sunovion Pharmaceuticals Basic Information List
Table Sunovion Pharmaceuticals Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Sunovion Pharmaceuticals Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Sunovion Pharmaceuticals Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Sunovion Pharmaceuticals Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Pulmonary Drugs
Figure Manufacturing Process Analysis of Pulmonary Drugs
Figure Pulmonary Drugs Industrial Chain Analysis
Table Raw Materials Sources of Pulmonary Drugs Major Players/Suppliers in 2017
Table Major Buyers of Pulmonary Drugs
Table Distributors/Traders List
Figure United States Pulmonary Drugs Sales Volume (K Units) and Growth Rate Forecast (2018-2025)
Figure United States Pulmonary Drugs Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Pulmonary Drugs Price (USD/Unit) Trend Forecast (2018-2025)
Table United States Pulmonary Drugs Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Pulmonary Drugs Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Pulmonary Drugs Sales Volume (K Units) Forecast by Type in 2025
Table United States Pulmonary Drugs Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Pulmonary Drugs Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Pulmonary Drugs Sales Volume (K Units) Forecast by Application in 2025
Table United States Pulmonary Drugs Sales Volume (K Units) Forecast by Region (2018-2025)
Table United States Pulmonary Drugs Sales Volume Share Forecast by Region (2018-2025)
Figure United States Pulmonary Drugs Sales Volume Share Forecast by Region (2018-2025)
Figure United States Pulmonary Drugs Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
Figure Product Picture of Pulmonary Drugs
Figure United States Pulmonary Drugs Market Size (K Units) by Type (2013-2025)
Figure United States Pulmonary Drugs Sales Volume Market Share by Type (Product Category) in 2017
Figure Inhaled Corticosteroids (ICS) Product Picture
Figure Long-Acting Beta2-Agonists (LABA) Product Picture
Figure Antihistamine Product Picture
Figure Vasodilators Product Picture
Figure Short-Acting Beta2-Agonists (SABA) Product Picture
Figure Anticholinergics Product Picture
Figure Combination Drugs Product Picture
Figure MAbs Product Picture
Figure Enzymes Product Picture
Figure Antibiotics & Antileukotrienes Product Picture
Figure United States Pulmonary Drugs Market Size (K Units) by Application (2013-2025)
Figure United States Sales Market Share of Pulmonary Drugs by Application in 2017
Figure Asthma & COPD Examples
Table Key Downstream Customer in Asthma & COPD
Figure Allergic Rhinitis Examples
Table Key Downstream Customer in Allergic Rhinitis
Figure Pulmonary Arterial Hypertension Examples
Table Key Downstream Customer in Pulmonary Arterial Hypertension
Figure Cystic Fibrosis Examples
Table Key Downstream Customer in Cystic Fibrosis
Figure United States Pulmonary Drugs Market Size (Million USD) by Region (2013-2025)
Figure The West Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Pulmonary Drugs Sales (K Units) and Growth Rate (2013-2025)
Figure United States Pulmonary Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Pulmonary Drugs Market Major Players Product Sales Volume (K Units) (2013-2018)
Table United States Pulmonary Drugs Sales (K Units) of Key Players/Suppliers (2013-2018)
Table United States Pulmonary Drugs Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Pulmonary Drugs Sales Share by Players/Suppliers
Figure 2017 United States Pulmonary Drugs Sales Share by Players/Suppliers
Figure United States Pulmonary Drugs Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Pulmonary Drugs Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Pulmonary Drugs Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Pulmonary Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Pulmonary Drugs Revenue Share by Players/Suppliers
Table United States Market Pulmonary Drugs Average Price (USD/Unit) of Key Players/Suppliers (2013-2018)
Figure United States Market Pulmonary Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2017
Figure United States Pulmonary Drugs Market Share of Top 3 Players/Suppliers
Figure United States Pulmonary Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Pulmonary Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Pulmonary Drugs Product Category
Table United States Pulmonary Drugs Sales (K Units) by Region (2013-2018)
Table United States Pulmonary Drugs Sales Share by Region (2013-2018)
Figure United States Pulmonary Drugs Sales Share by Region (2013-2018)
Figure United States Pulmonary Drugs Sales Market Share by Region in 2017
Table United States Pulmonary Drugs Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Pulmonary Drugs Revenue Share by Region (2013-2018)
Figure United States Pulmonary Drugs Revenue Market Share by Region (2013-2018)
Figure United States Pulmonary Drugs Revenue Market Share by Region in 2017
Table United States Pulmonary Drugs Price (USD/Unit) by Region (2013-2018)
Table United States Pulmonary Drugs Sales (K Units) by Type (2013-2018)
Table United States Pulmonary Drugs Sales Share by Type (2013-2018)
Figure United States Pulmonary Drugs Sales Share by Type (2013-2018)
Figure United States Pulmonary Drugs Sales Market Share by Type in 2017
Table United States Pulmonary Drugs Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Pulmonary Drugs Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Pulmonary Drugs by Type (2013-2018)
Figure Revenue Market Share of Pulmonary Drugs by Type in 2017
Table United States Pulmonary Drugs Price (USD/Unit) by Types (2013-2018)
Figure United States Pulmonary Drugs Sales Growth Rate by Type (2013-2018)
Table United States Pulmonary Drugs Sales (K Units) by Application (2013-2018)
Table United States Pulmonary Drugs Sales Market Share by Application (2013-2018)
Figure United States Pulmonary Drugs Sales Market Share by Application (2013-2018)
Figure United States Pulmonary Drugs Sales Market Share by Application in 2017
Table United States Pulmonary Drugs Sales Growth Rate by Application (2013-2018)
Figure United States Pulmonary Drugs Sales Growth Rate by Application (2013-2018)
Table AstraZeneca plc Basic Information List
Table AstraZeneca plc Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure AstraZeneca plc Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure AstraZeneca plc Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure AstraZeneca plc Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Bayer AG Basic Information List
Table Bayer AG Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Bayer AG Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Bayer AG Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Bayer AG Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Teva Pharmaceutical Industries Ltd Basic Information List
Table Teva Pharmaceutical Industries Ltd Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Teva Pharmaceutical Industries Ltd Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Teva Pharmaceutical Industries Ltd Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Teva Pharmaceutical Industries Ltd Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Actelion Pharmaceuticals, Inc. Basic Information List
Table Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Actelion Pharmaceuticals, Inc. Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Boehringer Ingelheim GmbH Basic Information List
Table Boehringer Ingelheim GmbH Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Boehringer Ingelheim GmbH Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Boehringer Ingelheim GmbH Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Boehringer Ingelheim GmbH Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table F. Hoffmann-La Roche Ltd. Basic Information List
Table F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Merck & Co., Inc. Basic Information List
Table Merck & Co., Inc. Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Merck & Co., Inc. Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Merck & Co., Inc. Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Merck & Co., Inc. Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Novartis AG Basic Information List
Table Novartis AG Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Novartis AG Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Novartis AG Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Novartis AG Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table GlaxoSmithKline plc Basic Information List
Table GlaxoSmithKline plc Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure GlaxoSmithKline plc Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure GlaxoSmithKline plc Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure GlaxoSmithKline plc Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Sunovion Pharmaceuticals Basic Information List
Table Sunovion Pharmaceuticals Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Sunovion Pharmaceuticals Pulmonary Drugs Sales Growth Rate (2013-2018)
Figure Sunovion Pharmaceuticals Pulmonary Drugs Sales Market Share in United States (2013-2018)
Figure Sunovion Pharmaceuticals Pulmonary Drugs Revenue Market Share in United States (2013-2018)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Pulmonary Drugs
Figure Manufacturing Process Analysis of Pulmonary Drugs
Figure Pulmonary Drugs Industrial Chain Analysis
Table Raw Materials Sources of Pulmonary Drugs Major Players/Suppliers in 2017
Table Major Buyers of Pulmonary Drugs
Table Distributors/Traders List
Figure United States Pulmonary Drugs Sales Volume (K Units) and Growth Rate Forecast (2018-2025)
Figure United States Pulmonary Drugs Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Pulmonary Drugs Price (USD/Unit) Trend Forecast (2018-2025)
Table United States Pulmonary Drugs Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Pulmonary Drugs Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Pulmonary Drugs Sales Volume (K Units) Forecast by Type in 2025
Table United States Pulmonary Drugs Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Pulmonary Drugs Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Pulmonary Drugs Sales Volume (K Units) Forecast by Application in 2025
Table United States Pulmonary Drugs Sales Volume (K Units) Forecast by Region (2018-2025)
Table United States Pulmonary Drugs Sales Volume Share Forecast by Region (2018-2025)
Figure United States Pulmonary Drugs Sales Volume Share Forecast by Region (2018-2025)
Figure United States Pulmonary Drugs Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources